Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „riociguat“
Suchtreffer
Begriffe & Kennungen
Adempas · 4.5 · Riociguat and its main metabolite are not inhibitors or inducers of major CYP isoforms (including CYP 3A4) or
Eintrag öffnenAdempas · 4.5 · Riociguat and its main metabolite are strong inhibitors of CYP1A1 in vitro. Therefore, clinically relevant dru
Eintrag öffnenAdempas · 4.5 · Riociguat and its main metabolite are strong inhibitors of CYP1A1 in vitro. Therefore, clinically relevant dru
Eintrag öffnenAdempas · 4.5 · Riociguat is cleared mainly via cytochrome P450-mediated (CYP1A1, CYP3A4, CYP3A5, CYP2J2) oxidative metabolism
Eintrag öffnenAdempas · 4.5 · Riociguat is cleared mainly via cytochrome P450-mediated (CYP1A1, CYP3A4, CYP3A5, CYP2J2) oxidative metabolism
Eintrag öffnenAdempas · 4.5 · Smoking In cigarette smokers riociguat exposure is reduced by 50-60% (see section 5.2). Therefore, patients ar
Eintrag öffnenAdempas · 4.5 · Soluble guanylate cyclase stimulators Concomitant use of riociguat with other soluble guanylate cyclase stimul
Eintrag öffnenAdempas · 4.5 · Soluble guanylate cyclase stimulators Concomitant use of riociguat with other soluble guanylate cyclase stimul
Eintrag öffnenAdempas · 4.5 · The concomitant use of riociguat with strong CYP3A4 inducers (e.g. phenytoin, carbamazepine, phenobarbitone or
Eintrag öffnenAdempas · 4.5 · The concomitant use of riociguat with strong CYP3A4 inducers (e.g. phenytoin, carbamazepine, phenobarbitone or
Eintrag öffnenAdempas · 4.5 · Warfarin/phenprocoumon Concomitant treatment of riociguat and warfarin did not alter prothrombin time induced
Eintrag öffnenAdempas · 4.5 · Warfarin/phenprocoumon Concomitant treatment of riociguat and warfarin did not alter prothrombin time induced
Eintrag öffnenAdempas · 4.8 · Table 1: Adverse reactions reported with riociguat in adult patients in phase III studies (pooled CHEST 1 and
Eintrag öffnenAdempas · 4.8 · Table 3: Adverse reactions reported with riociguat in adult patients in phase III studies (pooled CHEST 1 and
Eintrag öffnenAdempas · 4.8 · The adverse reactions reported with riociguat are listed in the table below by MedDRA system organ class and b
Eintrag öffnenAdempas · 4.8 · The adverse reactions reported with riociguat are listed in the table below by MedDRA system organ class and b
Eintrag öffnenAdempas · 4.8 · The most commonly reported adverse reactions, occurring in ≥ 10% of patients under riociguat treatment (up to
Eintrag öffnenAdempas · 4.8 · The most commonly reported adverse reactions, occurring in ≥ 10% of patients under riociguat treatment (up to
Eintrag öffnenAdempas · 4.8 · The safety of riociguat has been investigated in 24 paediatric patients aged 6 to less than 18 years over 24 w
Eintrag öffnenAdempas · 4.8 · The safety of riociguat has been investigated in 24 paediatric patients aged 6 to less than 18 years over 24 w
Eintrag öffnen